Abstract: The invention provides a composition, and method of use thereof, comprising self-antigen displaying nanoparticles to target auto-reactive immune components for treating and/or preventing the autoimmune diseases associated therewith. The nanoparticles can also be loaded with cytotoxic drugs for targeted cell killing or with immune-tolerizing compounds to normalize the immune regulation.
Type:
Grant
Filed:
August 20, 2015
Date of Patent:
April 29, 2025
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Liangfang Zhang, Che-Ming Jack Hu, Jonathan Copp, Ronnie H. Fang, Brian T. Luk
Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
Type:
Grant
Filed:
August 30, 2024
Date of Patent:
April 29, 2025
Assignee:
Immunome, Inc.
Inventors:
Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
Abstract: Provided are arginine depletion agents such as ADI-PEG for use in combination with cancer immunotherapies, for example, immune checkpoint modulators and T-cell adoptive immunotherapies, for treating various cancers. Also provided are related methods, compositions, patient care kits, and cell cultures.
Abstract: The disclosure provides a cancer vaccine composition comprising inactivated cancer cells and an adjuvant, wherein the inactivated cancer cells are incapable of replication. Also provided is a method for producing a cancer vaccine composition, the method comprising contacting cancer cells with light (e.g., UV light) in the presence of a photosensitizer (e.g., riboflavin).
Type:
Grant
Filed:
March 21, 2019
Date of Patent:
April 22, 2025
Assignee:
Colorado State University Research Foundation
Inventors:
Terry Opgenorth, Amanda Guth, Raymond Goodrich
Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
Type:
Grant
Filed:
August 30, 2024
Date of Patent:
April 22, 2025
Assignee:
Immunome, Inc.
Inventors:
Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
Type:
Grant
Filed:
August 30, 2024
Date of Patent:
April 15, 2025
Assignee:
Immunome, Inc.
Inventors:
Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
Type:
Grant
Filed:
August 30, 2024
Date of Patent:
April 8, 2025
Assignee:
Immunome, Inc.
Inventors:
Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
Abstract: Disclosed is a non-natural amatoxin-type antibody conjugate, said conjugate similar to the natural amatoxin is linked to a biopharmaceutically acceptable salt with a target biomolecule so as to obtain stability in blood plasma, and efficiently kill tumor cells in cells.
Type:
Grant
Filed:
August 18, 2018
Date of Patent:
April 8, 2025
Assignee:
SYSTIMMUNE, INC.
Inventors:
Yi Zhu, Jie Li, Yongguo Yu, Weijia Liu, Shi Zhuo
Abstract: Novel anti-tumor agents comprising at least one ligand of the B7h receptor, wherein the ligand of receptor B7h is loaded in a biocompatible micro- or nano-carrier and is able of binding to receptor B7h and triggering receptor B7h activity.
Type:
Grant
Filed:
January 9, 2019
Date of Patent:
April 1, 2025
Assignee:
NOVAICOS IMMUNOTHERAPEUTICS S.R.L.
Inventors:
Umberto Dianzani, Casimiro Luca Gigliotti, Elena Boggio, Nausicaa Clemente, Annalisa Chiocchetti, Francesco Trotta, Roberta Cavalli, Chiara Dianzani
Abstract: The invention relates to an immunogenic compound comprising an antigenic peptide having amino acid similarity with a tumor antigen, which antigenic peptide is selected in the group consisting of sequences described in the specification.
Type:
Grant
Filed:
August 30, 2022
Date of Patent:
April 1, 2025
Assignee:
ENTEROME S.A.
Inventors:
Laurent Chene, Alban Mathieu, Matthieu Pichaud, Francesco Strozzi
Abstract: Methods of treating cancer or enhancing sensitivity to cancer therapies, including immunotherapies by increasing tumor mutation burden, are provided. The methods use therapeutics directed against DNA polymerase proofreading and/or mismatch repair enzymes such as MLH1, MSH2, MSH6 or PMS2. The therapeutics can be used alone, in tandem or in combination with other cancer therapies, in particular with immunotherapies. Also provided are antisense therapeutics targeting DNA polymerase proofreading and/or mismatch repair enzymes.
Abstract: Steroid acid-peptide conjugates covalently modified for improved stability and/or biological activity are described herein. Covalent modifications include the formation of multimeric compounds comprising at least two steroid acid-peptide monomers covalently bound to one another that behave as new chemical entities, as well as protecting one or more free thiol groups present in the steroid acid-peptide conjugates to improve their stability and/or biological activity.
Abstract: An antibody or antigen binding fragment thereof that binds to a Fn14, wherein the antibody or antigen binding fragment thereof is an antagonist and non-agonist of Fn14.
Type:
Grant
Filed:
December 19, 2019
Date of Patent:
February 25, 2025
Assignee:
KYOWA KIRIN CO., LTD.
Inventors:
Aihua Song, Andrew John McKnight, Rachel Soloff Nugent, John Lorca Laudenslager, Giuseppe Destito, Sarah Sunrise Bubeck, Shinya Ogawa, Yuji Yamazaki, David Mills, Aruna Bitra, Dirk Michael Zajonc
Abstract: The present invention provides an agent for inducing effector memory T cell or an agent for inducing MHC class I for treating or preventing a cancer, comprising a TLR7 agonist which is used with an immune checkpoint inhibitor. And, the present invention also provides a medicament for treating or preventing a cancer, comprising a TLR7 agonist which is used with an immune checkpoint inhibitor.
Abstract: The present disclosure relates to antibodies and antibody conjugates, for instance antibody drug conjugates, with binding specificity for receptor tyrosine kinase orphan receptor 1 (ROR1) and its isoforms and homologs, and compositions comprising the antibodies or antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibodies and antibody conjugates and compositions thereof as well as methods of using the antibodies and antibody conjugates and compositions thereof, such as in therapeutic and diagnostic methods.
Type:
Grant
Filed:
July 10, 2023
Date of Patent:
February 18, 2025
Assignee:
Sutro Biopharma, Inc.
Inventors:
Amandeep Gakhal, Abigail Yu, Ryan Stafford, Jeffrey Hanson, Alice Yam, Krishna Bajjuri, Andreas Maderna, Cristina Abrahams, Xiaofan Li, Gang Yin, Miao Wen, Kristin Bedard, Daniel Calarese, Helena Kiefel
Abstract: Disclosed herein are polypeptides, and methods of making and using such polypeptides, that comprise a bispecific antibody construct covalently linked to an extended recombinant polypeptide comprising a barcode fragment releasable from said polypeptide upon digestion by a protease, and a Release Segment that can be proteolytically cleaved wherein said cleavage releases the bispecific antibody construct from the extended recombinant polypeptide.
Type:
Grant
Filed:
October 25, 2023
Date of Patent:
February 4, 2025
Assignee:
Amunix Pharmaceuticals, Inc.
Inventors:
Volker Schellenberger, Eric Johansen, Angela Henkensiefken, Darragh Maccann, James McClory, Philipp Kuhn, Andre Frenzel, Bryan Irving, Mika Derynck
Abstract: Combined preparations for the treatment of cancer are described. The combined preparations comprise: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) an anti-neoplastic agent, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor. Methods for the treatment of cancer using the combined preparations are also described.
Abstract: The invention relates to a fusion protein containing a selective cell death-inducing enzyme system for use in the therapy and/or treatment of cancer and tumors in humans and animals, a process, and its use.
Abstract: Provided is a treatment of cancer using a dual modulator of Insulin Receptor Substrate (IRS) and signal transducer and activator of transcription 3 (Stat3), as well with other agents. The combination can be used to treat a tumor that has developed resistance to an EGFR inhibitor, EGFR antibody, mTOR inhibitor, MEK inhibitor, mutated B-Raf inhibitor, chemotherapeutic agents, and certain combinations thereof, or to prevent acquired resistance of a tumor to any of said inhibitors or agents, or to prevent tumor recurrence following cease of treatment with any of said inhibitors or agents or a combination thereof. The subject matter further provides a treatment of cancer using combination therapy comprising a dual modulator of IRS and Stat3, in combination with an immunotherapy agent. The combination can be used to sensitize a tumor to immunotherapy.
Type:
Grant
Filed:
January 27, 2021
Date of Patent:
January 21, 2025
Assignee:
TYRNOVO LTD.
Inventors:
Hadas Reuveni, Izhak Haviv, Lana Kupershmidt
Abstract: Provided in the present invention are an anti-OX40 monoclonal antibody or an antigen-binding fragment thereof, and a corresponding isolated polynucleotide, expression vector, recombinant cell, pharmaceutical composition, and application thereof. The present antibody can be used for the treatment of cancer or autoimmune disease.